Littérature scientifique sur le sujet « MiRna, Primary Myelofibrosis, Myeloproliferative Neoplasms »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « MiRna, Primary Myelofibrosis, Myeloproliferative Neoplasms ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "MiRna, Primary Myelofibrosis, Myeloproliferative Neoplasms"
Manaila, Roxana, Vlad Moisoiu, Erik Knutsen, Mihnea P. Dragomir et George A. Calin. « Diagnostic and Therapeutic MicroRNAs in Primary Myelofibrosis ». Proceedings of the Singapore National Academy of Science 14, no 02 (décembre 2020) : 91–109. http://dx.doi.org/10.1142/s2591722620400074.
Texte intégralNorfo, Ruggiero, Roberta Zini, Valentina Pennucci, Elisa Bianchi, Simona Salati, Paola Guglielmelli, Andrea Bisognin et al. « Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis. » Blood 120, no 21 (16 novembre 2012) : 2854. http://dx.doi.org/10.1182/blood.v120.21.2854.2854.
Texte intégralZini, Roberta, Ruggiero Norfo, Valentina Pennucci, Elisa Bianchi, Simona Salati, Paola Guglielmelli, Andrea Bisognin et al. « Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis ». Blood 122, no 21 (15 novembre 2013) : 1600. http://dx.doi.org/10.1182/blood.v122.21.1600.1600.
Texte intégralHarada, Kayo Shirado, Kazuhiko Ikeda, Kazuei Ogawa, Hideyoshi Noji, Hideo Kimura, Tatsuyuki Kai, Soji Morishita, Norio Komatsu et Yasuchika Takeishi. « The Role Of Deregulated HMGA2 Expression With Promoter Methylation Of p16 In Myeloproliferative Neoplasms ». Blood 122, no 21 (15 novembre 2013) : 1606. http://dx.doi.org/10.1182/blood.v122.21.1606.1606.
Texte intégralRontauroli, Sebastiano, Ruggiero Norfo, Valentina Pennucci, Roberta Zini, Samantha Ruberti, Elisa Bianchi, Simona Salati et al. « MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells ». Blood 128, no 22 (2 décembre 2016) : 4272. http://dx.doi.org/10.1182/blood.v128.22.4272.4272.
Texte intégralHarada, Kayo Shirado, Kazuhiko Ikeda, Kazuei Ogawa, Hiroshi Ohkawara et Yasuchika Takeishi. « Dysregulation of the Let-7/HMGA2 Axis with Methylation of p16 Promoter As a Possible Target of Histone Deacetylase Inhibitor in Myeloproliferative Neoplasms ». Blood 124, no 21 (6 décembre 2014) : 3213. http://dx.doi.org/10.1182/blood.v124.21.3213.3213.
Texte intégralVisani, Giuseppe, Alessandro Isidori, Maria Rosaria Sapienza, Simona Righi, Antonella Laginestra, Claudio Agostinelli, Elena Sabattini et al. « Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. » Blood 114, no 22 (20 novembre 2009) : 1890. http://dx.doi.org/10.1182/blood.v114.22.1890.1890.
Texte intégralCosta Villela, Neysimelia, Gustavo Zamperlini, Patrícia Shimoda Ikeuti, Roseane Vasconcelos Gouveia, Simone De Castro Resende Franco et Luiz Fernando Lopes. « Myeloproliferative neoplasms ». JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY 2, no 4 (30 novembre 2021) : 129. http://dx.doi.org/10.46765/2675-374x.2021v2n4p129.
Texte intégralStein, Brady L., et Alison R. Moliterno. « Primary Myelofibrosis and the Myeloproliferative Neoplasms ». JAMA 303, no 24 (23 juin 2010) : 2513. http://dx.doi.org/10.1001/jama.2010.853.
Texte intégralKiladjian, Jean-Jacques. « The spectrum of JAK2-positive myeloproliferative neoplasms ». Hematology 2012, no 1 (8 décembre 2012) : 561–66. http://dx.doi.org/10.1182/asheducation.v2012.1.561.3807838.
Texte intégralThèses sur le sujet "MiRna, Primary Myelofibrosis, Myeloproliferative Neoplasms"
Pedrazzani, Fabiane Spagnol. « Impacto da análise molecular da mutação JAK2V617F no diagnóstico de neoplasias mieloproliferativas crônicas de acordo com os critérios da OMS 2016 ». reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2016. http://hdl.handle.net/10183/157653.
Texte intégralMyeloproliferative neoplasms (MPNs) are a group of disorders derived from a clonal transformation of stem cell on which myeloid cell lineage is predominantly expanded in the peripheral blood. Philadelphia-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) which share many hematological, clinical, and evolutionary characteristics. The JAK2 mutation (JAK2V617F) is present in about 95% of patients with PV, between 50 to 70% with ET and 40 to 50% PMF. However, the molecular diagnostic tests are often a challenge due to the high cost and the availability of specialized equipment. Objective: To verify the impact of molecular testing of the JAK2V617F mutation for the diagnosis of MPNs in patients attended at Hospital de Clinics, Porto Alegre. Methods: A total of 97 patients were evaluated with suspected of MPNs. The peripheral blood samples were analyzed for the JAK2V617F mutation by the molecular genetic allelespecific PCR method and the results correlated with the clinical-laboratory data. To establish the diagnosis, the 2016 World Health Organization (WHO) criteria were used. Results: Of the 87 patients evaluated, 27.6% were diagnosed as PV, 39.1% as ET, 4.6% as PMF and 28.7% did not meet criteria for MPNs diagnosis. Comparison of the use of the JAK2V617F test showed that only 41.7% of patients with PV without the mutation test were diagnosed compared to 91.7% using this test as one of the criteria for the final diagnosis (p = 0.004). In the ET and the PMF, this criterion was not statistically significant. Conclusion: The molecular test for the JAK2V617F mutation in our hospital had a significant impact in the diagnosis of patients with PV, showing to be an important tool for the final diagnosis of this MPN.
Orvain, Corentin. « Elaboration de nouveaux outils pour le diagnostic et le pronostic des patients atteints de syndrome myéloprolifératif. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms : a pragmatic study Sequential mutational evaluation of CALR-mutated myelopro-liferative neoplasms with thrombocytosis reveals an associa-tion between CALR allele burden evolution and diseaseprogression ». Thesis, Angers, 2019. http://www.theses.fr/2019ANGE0043.
Texte intégralVarious scoring systems have been successively elaborated to predict outcome of patients with chronic myeloid leukemia (CML). However, no link has been identified between those scores and CML biology. We show that high-risk patients have high GATA2 levels, in correlation with higher baseline basophil and platelet counts, two parameters used to calculate prognostic scores, and expression of genes involved in basophils. GATA2 expression increases in accelerated and myeloidblast-phase. Since some patients can now stop treatment, with a near 50% success rate, it is necessary to reevaluate the way we assess prognosis. A 6-month optimal molecular response was associated with an increased discontinuation attempt rate in our cohort. While the diagnosis of CML is fairly easy, it is often difficult to distinguish essential thrombocythemia (ET), pre-myelofibrosis and myelofibrosis. The numeration of CD34+ circulating cells is of interest in this setting : we show that a number < 10/μ excludes the diagnosis of myelofibrosis with a very good sensitivity (97%) and good specificity (90%). In a cohort of patients with ET and CALR mutation, We show that an increase in allele burden, and not additional mutations at diagnosis or during follow-up,is associated with an increased risk of progression. All of these parameters will be evaluated in a prospective multicentric study in order to elaborate a non-invasive diagnostic score to distinguish TE, pre-myélofibrosis, and myelofibrosis
MANNARELLI, CARMELA. « “MiRNA expression in Primary Myelofibrosis : characterization and pathophysiology implications” ». Doctoral thesis, 2016. http://hdl.handle.net/2158/1039412.
Texte intégralLivres sur le sujet "MiRna, Primary Myelofibrosis, Myeloproliferative Neoplasms"
Provan, Drew, Trevor Baglin, Inderjeet Dokal et Johannes de Vos. Myeloproliferative neoplasms. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0007.
Texte intégralProvan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos et Mammit Kaur. Myeloproliferative neoplasms. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199683307.003.0007_update_001.
Texte intégralMughal, Tariq I., et Tiziano Barbui, dir. Oxford Specialist Handbook : Myeloproliferative Neoplasms. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.001.0001.
Texte intégralCollins, Graham, et Chris Bunch. Myeloproliferative disorders. Sous la direction de Patrick Davey et David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0291.
Texte intégralChapitres de livres sur le sujet "MiRna, Primary Myelofibrosis, Myeloproliferative Neoplasms"
Barosi, Giovanni. « Conventional and Investigational Therapy for Primary Myelofibrosis ». Dans Myeloproliferative Neoplasms, 117–38. Totowa, NJ : Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-266-7_6.
Texte intégralTefferi, Ayalew. « Myeloproliferative Neoplasms : Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis ». Dans Practical Hemostasis and Thrombosis, 147–56. Oxford, UK : Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9781444306286.ch14.
Texte intégralTibes, Raoul, Gurcharan Singh Khera et Ruben A. Mesa. « Myeloproliferative Neoplasms : Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis ». Dans Textbook of Uncommon Cancer, 647–58. Hoboken, NJ, USA : John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118464557.ch47.
Texte intégralHarrison, Claire, Yan Beauverd et Donal McLorran. « Myelofibrosis ». Dans Oxford Specialist Handbook : Myeloproliferative Neoplasms, 126–50. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.003.0009.
Texte intégralJasielec, Jagoda, et Olatoyosi Odenike. « Primary, Post-PV, and Post-ET Myelofibrosis : Clinical Features, Prognosis, and Conventional Therapy ». Dans Contemporary Management of Myeloproliferative Neoplasms, 102. Jaypee Brothers Medical Publishers (P) Ltd., 2015. http://dx.doi.org/10.5005/jp/books/12391_6.
Texte intégralAbdelwahab, Omar, Raajit Rampal, Catriona Jamieson et Tariq I. Mughal. « Transformation of myeloproliferative neoplasms to acute leukaemia ». Dans Oxford Specialist Handbook : Myeloproliferative Neoplasms, 222–33. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.003.0014.
Texte intégralEgan, Daniel, et Jerald P. Radich. « Monitoring efforts in myeloproliferative neoplasms ». Dans Oxford Specialist Handbook : Myeloproliferative Neoplasms, 234–48. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.003.0015.
Texte intégralKvasnicka, Hans Michael, et Jürgen Thiele. « Haematopathology of classic myeloproliferative neoplasms ». Dans Oxford Specialist Handbook : Myeloproliferative Neoplasms, 45–62. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.003.0004.
Texte intégralBesses, Carlos, Beatriz Bellosillo, Alberto Alvarez-Larrán et Tariq I. Mughal. « Essential thrombocythaemia ». Dans Oxford Specialist Handbook : Myeloproliferative Neoplasms, 151–67. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.003.0010.
Texte intégralHoover, Kevin B. « Lymphoproliferative and Myeloproliferative Disorders ». Dans Musculoskeletal Imaging Volume 2, sous la direction de Kevin B. Hoover, 44–49. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190938178.003.0078.
Texte intégral